Drug Trial Radar · NCT06239220
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Feb 16, 2024
Primary completion
Dec 31, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ImmunityBio, Inc.
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies involved in this study are: * PD-L1 t-haNK cell therapy (a NK cell therapy infusion) * NAI (a type of recombinant human superagonist) * Cetuximab (a type of antibody)
Conditions
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
PD-L1 t-haNKBiological
Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
CetuximabDrug
Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
NAIBiological
Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Disease will be evaluated through imaging every 2 cycles on day 1 and 15 (each cycle is 28 days) and through study completion (an average of 1 year). ORR expected to be observed up to 1 year.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.